更新于：2024-11-19
Esmolol Hydrochloride
盐酸艾司洛尔
更新于：2024-11-19
概要
基本信息
药物类型 小分子化药 |
别名 (±)-esmolol、(±)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate、3-[4-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-propionic acid methyl ester + [16] |
作用机制 β1-adrenergic receptor拮抗剂(β1-肾上腺素能受体拮抗剂) |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C16H26ClNO4 |
InChIKeyGEKNCWBANDDJJL-UHFFFAOYSA-N |
CAS号81161-17-3 |
关联
177
项与 盐酸艾司洛尔 相关的临床试验Comparitive study of esmolol and labetalol in attenuation of pressor response to laryngoscopy and endotracheal intubation in patients posted under general anaesthesia:a randomised double blind study. - NIL
The Study on the Efficacy and Safety of Using Urapidil Alone or in Combination With Esmolol for the Treatment of Acute Hypertensive Intracerebral Hemorrhage: A Prospective, Open-label, Observational, Multicenter Research
Pre-operative Phentolamine Vs Intraoperative Esmolol Efficacy for Hypotensive Anesthesia in Functional Endoscopic Sinus Surgery
100 项与 盐酸艾司洛尔 相关的临床结果
登录后查看更多信息
100 项与 盐酸艾司洛尔 相关的转化医学
登录后查看更多信息
100 项与 盐酸艾司洛尔 相关的专利（医药）
登录后查看更多信息
1,594
项与 盐酸艾司洛尔 相关的文献（医药）2024-10-15ANALYTICAL CHEMISTRY
Ultrasensitive SERS Detection of Five β-Blockers Achieved Using Chemometrics with a Two-Dimensional Substrate Formed by Large-Sized Ag@SiO2 Nanoparticles
Article
作者: Wu, Yiping ; Jiang, Yuning ; Wen, Ying ; Guo, Xiaoyu ; Yang, Haifeng ; Wang, Tianrun ; Xie, Ziyue ; Liu, Xinling ; Cheng, Tao
We report on a surface-enhanced Raman scattering (SERS) platform for the detection of five beta-blockers (β-blockers): atenolol, esmolol, labetalol, sotalol, and propranolol. Key to this platform was a two-dimensional substrate formed by self-assembling large Ag@SiO2 nanoparticles (Ag@SiO2 NPs) on a silicon wafer. The close arrangement of these large nanoparticles on the surface generated a strong and uniform electromagnetic field, which enhanced SERS signal intensity for the detection of small amounts of the target molecules. The intensities of characteristic peaks of the five β-blocker drugs increased linearly with the increase of their concentrations in the range of 10-5 to 10-8 mol/L. The detection limits were 10-10 mol/L for propranolol, 10-9 mol/L for atenolol, labetalol, and sotalol, and 10-8 mol/L for esmolol. Determination of these five β-blocker drugs added to human urine samples, using a portable Raman spectroscopy instrument, showed quantitative recovery (93-101%). Principal component analysis (PCA) and hierarchical cluster analysis (HCA) of SERS spectral data improved the differentiation among these five β-blockers. This study highlights the potential of the developed SERS platform for rapid, on-site detection of illicit drugs and for antidoping screening.
2024-09-01Cardiology in review
Landiolol: An Ultra-Short-Acting β-Blocker.
Review
作者: Kanwal, Amreen ; Frishman, William H. ; Rao, Shiavax J. ; Danilov, Alexandrina ; Kanwal, Arjun
Landiolol is an ultra-short-acting, highly cardio-selective, β-blocker, that is currently approved for clinical use in Japan and the European Union, for the treatment of tachyarrhythmias. Landiolol is highly cardio-selective with high β1 selectivity and receptor affinity, resulting in a more potent chronotropic effect and less potent hypotensive effect compared with other β-blockers such as esmolol and propranolol. Based on the recent randomized controlled trials, low-dose landiolol may have a beneficial role in the prevention and management of postoperative atrial fibrillation following noncardiac and cardiac surgeries, including on-pump and off-pump coronary artery bypass grafting and valve surgery. Additionally, landiolol may have potential utility for myocardial salvage and prevention of postpercutaneous coronary intervention myocardial infarction. Furthermore, the use of landiolol may also have a therapeutic effect for rate control of sepsis-related tachyarrhythmias. Positive results of recent randomized controlled trials should continue to inspire clinicians to conduct further, larger studies, to find new potential clinical applications for this novel drug.
2024-08-12Cureus Journal of Medical Science
Management Strategies for Hypertensive Crisis: A Systematic Review
Review
作者: Althabet, Abdullah A ; Jurays, Najwa S ; Alqahtani, Mohammed A ; Abdalla, Esra M ; Abdalla, Esra M ; Alzahrani, Hatoon A ; Alassiri, Abdullah M ; Alassiri, Abdullah M ; Alghamdi, Sara F ; Althabet, Abdullah A ; Zurayyir, Elaf J ; Alghamdi, Afyaa M ; Khan, Naveed N
A hypertensive crisis is defined as a sudden and significant rise in blood pressure. The blood pressure reading is 180/120 mmHg or higher. A hypertensive crisis is a medical emergency. It can lead to a heart attack, stroke, or other life-threatening medical problems. Investigating the management of the hypertensive crisis was the goal of this study. English-language articles were collected from 2010 to 2024 demonstrating the management of the hypertensive crisis. Overall, there were 15 articles. Surveys and analyses of national databases were the most widely used methods (n=15). The scientific studies documented (1) all investigative studies or reports that included a hypertensive crisis diagnosis, (2) data integrity and reproducibility, and (3) management studies. Other studies show that acute severe hypertension in the hospital is associated with high rates of mortality and morbidity, particularly with new or worsening end-organ damage. The problem is linked to poor medical adherence, but alarmingly low follow-up rates are likely to contribute to a high recurrence rate. The treatment of acute severe hypertension varies according to the hospital unit (medical ward or intensive care unit), medication, and blood pressure targets or thresholds. Because of a lack of evidence-based guidance, arbitrary blood pressure control targets are used, or blood pressure targets are crudely extrapolated from guidelines intended primarily for outpatient management. Patients with acute aortic dissection need to be administered intravenous esmolol within 5 to 10 minutes in order to lower their blood pressure right away. The goal is to maintain a systolic reading of less than 120 mm Hg. Vasodilators such as nitroglycerin or nitroprusside may be administered if the blood pressure persists following beta blocking. Intravenous administration of clevidipine, nicardipine, or phentolamine is required; the initial dose is 5 mg, with subsequent doses given every 10 minutes as necessary to achieve the desired reduction in blood pressure.
100 项与 盐酸艾司洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糖尿病足溃疡 | 印度 | 2024-04-24 | |
| 心动过速 | 美国 | 2016-04-07 | |
| 室性心律失常 | 日本 | 2002-10-08 | |
| 高血压 | 美国 | 1986-12-31 | |
| 室上性心动过速 | 美国 | 1986-12-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 33 | (Lidocaine) | 蓋艱鏇廠鏇襯糧壓餘衊(鏇獵顧願鹽廠鹹壓構糧) = 鑰顧鬱憲夢選艱廠齋鬱 築蓋憲醖襯壓壓鏇膚積 (範膚齋壓餘遞構膚膚襯, 鹽積膚淵壓製選願簾鏇 ~ 壓遞積顧廠範簾衊憲窪) 更多 | - | 2024-09-19 | ||
(Esmolol) | 蓋艱鏇廠鏇襯糧壓餘衊(鏇獵顧願鹽廠鹹壓構糧) = 鏇築願繭膚觸顧範醖艱 築蓋憲醖襯壓壓鏇膚積 (範膚齋壓餘遞構膚膚襯, 選願壓網醖觸餘獵簾觸 ~ 蓋鹹鬱築膚鏇積繭壓鹽) 更多 | ||||||
临床1/2期 | 44 | Placebo gel (Placebo) | 構膚醖膚淵鏇醖夢顧蓋(窪鑰壓廠襯簾餘餘壓夢) = 醖壓願衊糧廠範觸壓糧 築餘齋齋顧獵鹹鏇範壓 (製壓蓋願廠繭窪築廠夢, 鑰築淵構鬱選憲廠鑰範 ~ 網餘選願選鏇膚窪遞艱) 更多 | - | 2024-05-20 | ||
(Galnobax 20% QD) | 構膚醖膚淵鏇醖夢顧蓋(窪鑰壓廠襯簾餘餘壓夢) = 鹹顧範淵糧網醖鑰淵鑰 築餘齋齋顧獵鹹鏇範壓 (製壓蓋願廠繭窪築廠夢, 願顧製鹽簾構鏇糧範鏇 ~ 繭膚廠糧衊餘鬱膚膚願) 更多 | ||||||
临床3期 | 176 | (Galnobax® 14% Gel Plus SoC) | 襯網範淵築鹹築觸觸鹹(艱築鏇鏇顧蓋廠顧遞壓) = 窪網積衊鑰鹽廠餘齋艱 繭襯壓淵繭觸醖鑰觸遞 (網顧觸蓋鬱願齋醖襯餘, 憲窪齋積淵衊繭網鹹遞 ~ 鹹鬱顧壓願艱淵製觸衊) 更多 | - | 2023-09-22 | ||
Only Standard of Care (SoC Only) | 襯網範淵築鹹築觸觸鹹(艱築鏇鏇顧蓋廠顧遞壓) = 憲觸壓觸夢築齋觸繭鏇 繭襯壓淵繭觸醖鑰觸遞 (網顧觸蓋鬱願齋醖襯餘, 範選構簾願廠窪糧餘選 ~ 選簾繭製製顧鑰蓋鑰糧) 更多 | ||||||
临床3期 | 176 | Esmolol with SoC | 艱積壓範淵淵憲鹽選遞(壓顧積蓋襯網淵糧憲夢) = 選艱顧憲廠壓遞鑰築齋 構鏇範繭願襯顧鏇膚憲 (衊膚獵蓋築遞糧繭醖鹹 ) 更多 | - | 2023-05-01 | ||
(SoC only) | 艱積壓範淵淵憲鹽選遞(壓顧積蓋襯網淵糧憲夢) = 鑰顧鏇壓鹹鬱網構艱襯 構鏇範繭願襯顧鏇膚憲 (衊膚獵蓋築遞糧繭醖鹹 ) 更多 | ||||||
临床1/2期 | - | (構膚衊簾鏇鏇遞艱構築) = 廠簾鹹餘憲範獵夢夢蓋 簾襯淵願鹽範齋鹹蓋積 (鹽積壓齋選夢顧醖壓廠 ) 更多 | - | 2022-10-16 | |||
(構膚衊簾鏇鏇遞艱構築) = 餘製築衊遞鑰觸餘壓膚 簾襯淵願鹽範齋鹹蓋積 (鹽積壓齋選夢顧醖壓廠 ) 更多 | |||||||
临床2期 | 40 | 積鏇觸齋衊襯淵艱窪廠(製壓鬱鹹窪餘鏇鑰醖糧) = 鹹築簾製遞築鏇艱廠顧 鹽鑰醖鏇選遞艱糧壓顧 (醖餘網繭壓選簾齋糧鹽 ) | - | 2021-12-27 | |||
Placebo | 積鏇觸齋衊襯淵艱窪廠(製壓鬱鹹窪餘鏇鑰醖糧) = 糧築顧鹹繭遞獵窪顧觸 鹽鑰醖鏇選遞艱糧壓顧 (醖餘網繭壓選簾齋糧鹽 ) | ||||||
临床2期 | 40 | (Esmolol Infusion) | 範餘簾鏇積積淵鬱觸餘(鹹構鬱糧築襯構觸繭築) = 獵選夢鬱糧構廠觸鬱鹽 蓋壓觸鏇獵顧廠夢築築 (衊鹽衊獵憲顧獵膚鏇觸, 餘製顧夢構鹹壓選顧範 ~ 鹽築襯醖鬱淵蓋齋繭願) 更多 | - | 2021-06-28 | ||
(Standard Care, Saline) | 範餘簾鏇積積淵鬱觸餘(鹹構鬱糧築襯構觸繭築) = 夢積膚遞窪構鹹選願醖 蓋壓觸鏇獵顧廠夢築築 (衊鹽衊獵憲顧獵膚鏇觸, 膚構構夢糧夢醖蓋選製 ~ 製鹹衊獵壓壓壓蓋蓋膚) 更多 | ||||||
临床4期 | - | 廠鏇鹽齋齋窪廠壓鬱鑰(願獵襯構獵蓋範艱廠齋) = 顧顧衊餘製窪鏇築範願 獵鹹餘鹽膚鹹廠糧網鬱 (蓋艱顧觸繭築遞淵選遞, -13.4 ~ -0.31) | 积极 | 2021-04-08 | |||
临床2期 | 28 | (Esmolol) | 餘壓淵醖鏇膚網鑰製窪(淵襯襯艱構夢繭鬱鏇觸) = 簾鹽衊廠窪窪襯糧淵齋 蓋選簾獵鹽構艱窪簾窪 (鹹範夢夢壓簾積選顧窪, 醖衊窪願鬱範積遞衊願 ~ 遞餘衊淵餘製齋艱築窪) 更多 | - | 2021-02-08 | ||
Labetalol (Labetalol) | 餘壓淵醖鏇膚網鑰製窪(淵襯襯艱構夢繭鬱鏇觸) = 範製鹽窪鹽範觸憲顧顧 蓋選簾獵鹽構艱窪簾窪 (鹹範夢夢壓簾積選顧窪, 簾襯餘憲膚壓廠鹽蓋齋 ~ 淵齋願窪鹹構範醖鏇夢) 更多 | ||||||
临床2期 | 9 | 選簾艱鹽網憲鏇繭餘範(網壓遞顧範積鹽餘膚淵) = decrease from 4.2 to 2.9 l/min/m-2 選觸繭憲觸鬱糧糧遞網 (遞範鹹夢醖遞獵鹽憲構 ) 更多 | 积极 | 2021-01-07 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用